Back to AZNView Full Landscape
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
5 competitors in Relapsed/ Refractory Multiple Myeloma
ACTICAR T-Cell Therapy
CBDYTeclistamab
Phase 3JNJTECVAYLI
Phase 3CBDYCevostamab
Phase 1BMYiberdomide
ApprovedDrug Information
Target Indication
Relapsed/ Refractory Multiple Myeloma
Clinical Trial
NCT05850234Last updated: 2/9/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts